Biocytogen/Eucure Biopharma’s CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by …,

A phase II, non-randomized, multi-center clinical study will evaluate the use of YH001 in combination with Junshi Biosciences’ anti-PD-1 monoclonal …, A phase II, non-randomized, multi-center clinical study will evaluate the use of YH001 in combination with Junshi Biosciences’ anti-PD-1 monoclonal …, Read More

Scroll to Top